BioSpace News Archive

Gritstone bio, Inc. announced that the company’s Board of Directors has granted five employees nonqualified stock options to purchase an aggregate of 14,800 shares of its common stock with an exercise price of $4.90, which is equal to the closing price of Gritstone’s common stock on March 17, 2022, the grant date of the awards.

Replimune Group, Inc. today announced updated data from completed cohorts of the Phase 2 part of the IGNYTE clinical trial in non-melanoma skin cancer (NMSC) and melanoma.

Orchard Therapeutics today announced its intention to focus its hematopoietic stem cell (HSC) gene therapy platform exclusively on severe neurometabolic diseases and early research programs while also reporting its financial results for the quarter and year ended December 31, 2021.

Pathalys Pharma, Inc. today announced the executive leadership team for the newly formed company. Pathalys officially launched on March 1, 2022.

CartiHeal Ltd today announced that the U.S. Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for its Agili-C™ implant.

Omega Therapeutics, Inc. today announced the appointment of Kevin McManus as Chief Human Resources Officer and Ling Zeng, Esq., as Chief Legal and Administrative Officer.

Researchers studying immunity and inflammation now have a faster, easier alternative to traditional enzyme-linked immunosorbent assays (ELISAs) with new Promega bioluminescent assays launched today.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Nasdaq has halted trading of the company’s common stock.

Graybug Vision, Inc. announced a strategic update on its pipeline programs GB-102 in wet age-related macular degeneration, GB-401 in primary open-angle glaucoma, as well as its newly acquired assets in corneal disease, inherited retinal diseases, and geographic atrophy.

Biomind Labs to Present at Benzinga Psychedelics Capital Conference in the U.S. on April 19th 2022.